Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 155   

Articles published

BMY 61.14 -0.19 (-0.31%)
price chart
Bristol-Myers Squibb Earnings: Currency Headwinds Take The Shine Off ...
Bristol-Myers Squibb reported its 2104 fourth quarter results on January 27th. The company's revenues were down 4%, compared to the year-ago quarter.
Bristol-Myers Squibb's Buy Rating Reiterated at William Blair (BMY)  Intercooler
Bristol-Myers Squibb Stock Rating Reaffirmed by Zacks (BMY)  Ticker Report
Company News: Bristol-Myers Squibb Co (NYSE:BMY)
Celldex Therapeutics (CLDX) and Bristol-Myers Squibb Co (NYSE:BMY) announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational ...
Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1 ...  Nasdaq
Bristol-Myers Squibb Co (BMY) Updates FY15 Earnings Guidance
Bristol-Myers Squibb logo Bristol-Myers Squibb Co (NYSE:BMY) updated its FY15 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.55-1.70 for the period, compared to the Thomson Reuters consensus earnings per ...
Bristol-Myers Squibb Co Beats Analysts' Expectations In Q4 Earnings
Bristol-Myers Squibb Co (NYSE:BMY) outperformed analysts' estimates, as the company announced better-than-expected earnings and revenue for the fourth quarter of 2014.
UPDATE 1-Bristol-Myers issues cautious 2015 forecast due to strong dollar  Reuters
Pension charge, lower sales slash Bristol-Myers' Q4 profit
Bristol-Myers Squibb Co (BMY) Q4 Earnings Preview: Expect Earnings And ...
Bristol-Myers Squibb Co (NYSE:BMY) is set to announce its financials for the fourth quarter of fiscal year 2014 before the market opens for trading today.
Bristol-Myers Squibb CEO steps down, replaced by COO
The succession plan is familiar to Bristol-Myers Squibb BMY , and smoother than some of its past leadership changes. The outgoing chairman, James Cornelius, also previously served as the company's CEO, taking on the job after his predecessor, Peter ...
Bristol-Myers Squibb Appoints Giovanni Caforio, MD, Chief Executive Officer ...  MarketWatch
Bristol-Myers Squibb Co (NYSE:BMY) Misses Estimates, Stock Rallies
Bristol-Myers Squibb Co (NYSE:BMY) was one of the notable decliners in the trading session today. The stock plunged by close to 2 percent on the back of above average volumes which is seen as a bearish sign.
Bristol-Myers Squibb Co.'s(NYSE:BMY) new cancer drug, a hit or not?
It seems that Bristol-Myers Squibb Co (NYSE:BMY) has made a good decision to invest heavily in the immuno-oncology sector since it's paying off for the company.
Bristol-Myers Squibb jumps on Opdivo cancer drug test  MarketWatch
Option Bears Feel the Sting of Bristol-Myers Squibb Company (BMY) Rally  Schaeffers Research (blog)
Bristol-Myers Squibb Co. (BMY) Price Target Raised to $59 at Deutsche Bank
Deutsche Bank maintained a Hold rating on Bristol-Myers Squibb Co. (NYSE: BMY) and raised its price target to $59.00 (from $52.00).
US Food and Drug Administration Approves Bristol-Myers Squibb's EvotazTM ...
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 ...
FDA clears Bristol-Myers HIV-1 combo drug  Seeking Alpha (registration)